Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20068983 | 0.88 | RET (0.42) | RETKDM4EALDH1A1EPHX1EPHX2 | |
| SCHEMBL20147681 | 0.87 | RET (0.42) | RETKDM4EALDH1A1EPHX1EPHX2 | |
| SCHEMBL21651936 | 0.77 | RET (0.40) | RETALDH1A1EPHX1 | |
| SCHEMBL20158755 | 0.76 | RET (0.41) | RETKDM4EALDH1A1EPHX1EPHX2 | |
| SCHEMBL20068982 | 0.73 | KDM4E (0.44) | RETKDM4EEPHX1EPHX2 | |
| SCHEMBL20147677 | 0.72 | RET (0.43) | RETKDM4EEPHX1EPHX2 | |
| SCHEMBL20069696 | 0.71 | RET (0.41) | RETKDM4EEPHX1EPHX2HSD11B1 | |
| SCHEMBL20158493 | 0.71 | RET (0.44) | RET | |
| SCHEMBL20147476 | 0.70 | RET (0.40) | RETKDM4EEPHX1EPHX2HSD11B1 | |
| SCHEMBL21651931 | 0.70 | RET (0.45) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148445-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885KDM4E 547/4885ALDH1A1 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.